The study, led by Dr. Yelena Janjigian, aims to generate the clinical data necessary to support a future international Phase III trial. Cadonilimab, a PD-1/CTLA-4 bispecific antibody, is being positioned as a superior alternative to current standards of care. While the FLOT chemotherapy regimen currently serves as the baseline, it produces a pathologic complete response rate of only 19%, leaving nearly one-third of patients at risk of recurrence or death within two years.
Akeso Launches US Phase II Trial for Gastric Cancer Treatment
Akeso has partnered with Memorial Sloan Kettering Cancer Center to launch a Phase II clinical trial evaluating a cadonilimab-based combination regimen for patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma, marking a significant step in testing the drug’s potential as a perioperative therapy in the United States.
This trial builds on data from the Phase III COMPASSION-15 study and earlier neoadjuvant research. Beyond this gastric cancer initiative, Akeso is simultaneously expanding its US footprint by collaborating with the Dana-Farber Cancer Institute and Mass General Brigham to test cadonilimab in combination with DNA-based therapies for glioblastoma. These efforts underscore the company's strategy to utilize its bispecific antibody platform across diverse and aggressive oncological indications.
Comments (0)
No comments yet. Be the first!